Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.
Transgene's TG4050 demonstrated a strong clinical proof of principle in adjuvant head and neck cancer, with all 16 patients remaining disease-free after 24.1 months.
Transgene's TG4050, an individualized immunotherapy for head and neck cancer, shows promising Phase I data with a 24-month follow-up to be presented in Q4 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.